The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate.
The Gates Medical Research Institute (Gates MRI) has entered into an expanded, strategic collaboration with IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to streamline trial operations and accelerate its clinical portfolio.
The Gates Medical Research Institute (MRI) today announced the appointment of Charles Wells, MD, as Chief Medical Officer (CMO) and Head of Medical Development, effective May 15, 2026.
Krishnan (Krish) Ramanathan, who has served as Chief of Staff and Head of Development at Gates Medical Research Institute (MRI), has been named Interim Chief Executive Officer (CEO) of the organization.
We’re glad to announce that the Phase 3 clinical trial of the M72/AS01E tuberculosis (TB) vaccine candidate has reached full enrollment eleven months ahead of schedule– with approximately 20,000 participants enrolled.
